UBS Remains a Buy on Telix Pharmaceuticals Ltd. (TLPPF)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 08 2025
0mins
Source: Business Insider
Analyst Rating: UBS analyst Laura Sutcliffe has maintained a Buy rating on Telix Pharmaceuticals Ltd. with a price target of A$36.00, while the current share price is $13.25.
Market Consensus: The overall analyst consensus for Telix Pharmaceuticals indicates a Strong Buy rating with an average price target of $20.45, and Sutcliffe has a 56.39% success rate in her healthcare sector coverage.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
